AstraZeneca Invests $2.5 Billion in Beijing R&D and Biotech Collaborations

AstraZeneca ( (GB:AZN) ) just unveiled an announcement.

AstraZeneca has announced a $2.5 billion investment to establish a new global strategic R&D center in Beijing, marking its second in China and sixth worldwide. This initiative, in partnership with the Beijing Municipal Government, includes collaborations with biotech firms Harbour BioMed, Syneron Bio, and BioKangtai, and aims to advance life sciences in China. The investment will enhance AstraZeneca’s early-stage research and clinical development capabilities, supported by a state-of-the-art AI and data science laboratory. Additionally, AstraZeneca is forming a joint venture with BioKangtai to develop vaccines, marking its first vaccine manufacturing facility in China. This strategic move is expected to grow AstraZeneca’s Beijing workforce to 1,700 employees and strengthen its position in the global biopharmaceutical industry.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. It specializes in the discovery, development, and commercialization of prescription medicines, focusing on areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative medicines are available in over 125 countries and serve millions of patients worldwide.

YTD Price Performance: 14.21%

Average Trading Volume: 2,738,290

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: £183.7B

Learn more about AZN stock on TipRanks’ Stock Analysis page.